ClinicalTrials.gg
Not yet recruitingNCT07569965FRONTIERUpdated May 6, 2026

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

A Phase 2 interventional study of zamtocabtagene autoleucel (MB-CART2019.1) and Cyclophosphamide in Mantle Cell Lymphoma (MCL), sponsored by Miltenyi Biomedicine GmbH. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Miltenyi Biomedicine GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

FRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants

Read the detailed description

This is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma participants. Participants will be enrolled on the study after diagnosis and before the end of their second cycle of induction therapy.

Eligible patients will receive a single intravenous infusion of MB-CART2019.1 cells at a dose of 2.5x10\^6 cells/kg following lymphodepleting chemotherapy. The goal is 52 participants in total who receive MB-CART2019.1 therapy. Additional participants may be screened, consented, registered, and treated in order to reach accrual goals. Participants will be followed on the trial for 1-year post-infusion. Assessment of survival annually through 15 years after infusion will be completed using the CIBMTR infrastructure.

02

Conditions studied

  • Mantle Cell Lymphoma (MCL)

Keywords

  • CD19/CD20-directed CAR-T Cells
  • Zamtocabtagene autoleucel
  • B-Cell Non-Hodgkin Lymphoma
  • Chimeric Antigen Receptor
  • CAR
  • CAR-T Cell
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell
  • MCL
  • Immunotherapy
  • T cell infusion
  • High-risk
  • Mantle Cell Lymphoma
  • Frontline
  • TP53
03

In context

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

This study's planned enrollment of 52 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

Miltenyi Biomedicine GmbH is the lead sponsor of 20 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MCL requires histologic confirmation by either overexpression of cyclin D1 OR presence of t(11;14) (q13; q32) translocation

    1. Subject should have a tumor sample (at least 5 unstained slides of tissue or tissue block) available prior to MB-CART2019.1 infusion, preferably collected pre-induction.
    2. If archival tissue is not available, the patient may be enrolled after discussion with the protocol chair and/or protocol officer
  • High Risk Disease at diagnosis, defined as having at least ONE of the criteria below:

    1. High risk MIPI-c (as calculated by https://www.european-mcl.net/home/scores-mipi-mipi-c-19.html)
    2. Simplified MIPI high-risk ≥6.2
    3. TP53 mutation OR ≥50% TP53 expression by IHC
    4. Complex Karyotype [e.g. 3 or more cytogenetic abnormalities, excluding the presence or absence of t(11:14)]
    5. Ki67≥ 50%
    6. Blastoid or pleomorphic histology with Ki-67 ≥30%
    7. at diagnosis
    8. NOTCH1 mutation
  • Received 2 cycles of appropriate systemic induction therapy, which includes a CD20 antibody +/- cytotoxic therapy +/- oral targeted therapy (e.g., BTKi, immunomodulatory imid drugs), with the following considerations:

    1. CD20 antibody alone does not count towards a cycle of treatment
    2. Induction cycles do not have to be identical
    3. For BTKis and/or lenalidomide a cycle is defined as 14-28 days and will be based on institutional treatment regimens.
    4. Intrathecal chemotherapy will not count towards a cycle of treatment
    5. Radiation therapy will not count towards a cycle of treatment
  • (ECOG) performance status of 0 or 1 at screening. ECOG performance status of 2 at screening is allowed if the decrease in performance status is attributed to lymphoma
  • Disease response assessment of either complete response, partial response, or stable disease by Lugano 2014 criteria assessed by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) (preferred) or contrast enhanced CT scans including neck/chest/abdomen/pelvis [37] after 2 cycles of induction therapy. If the participant has history of CNS disease, then he/she must have no history of or active parenchymal disease on magnetic resonance imaging (MRI)

    a. Leptomeningeal alone disease is allowable if it is not clinically progressive or worsening from baseline assessment

  • A (as estimated by direct urine collection, Chronic Kidney Disease Epidemiology Collaboration [], or Cockcroft-Gault Equation or institutional standard) ≥ 45 mL/min
  • Subjects of childbearing or child fathering potential must be willing to practice from the time of enrollment on this study until the follow-up period of the study

Exclusion criteria

Exclusion Criteria:

  • Unable to give
  • Any disease progression that occurs during the first 2 induction cycles
  • A (as estimated by direct urine collection, Chronic Kidney Disease Epidemiology Collaboration [], or Cockcroft-Gault Equation or institutional standard) \< 45 mL/min
  • Cardiac (EF) \< 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Acquisition scan (MUGA) (if range is provided, the upper value of the range may be used for assessing eligibility)
  • Resting O2 saturation \< 92% on room air
  • Serum (ALT) / aspartate aminotransferase (AST) ≥ 5 times the (ULN) for age
  • Total >1.5 mg/dL, except in individuals with Gilbert's syndrome
  • (ANC) \< 1000/μL unless related to bone marrow infiltration by mantle cell lymphoma. No short-acting granulocyte colony-stimulating factor (G-CSF) use within 7 days of ANC evaluation
  • count \< 50,000/µL unless related to bone marrow infiltration or hypersplenism by mantle cell lymphoma. No transfusions within 7 days of assessment.
  • Absolute CD3 count \< 50/μL at screening
  • Absolute lymphocyte count (ALC) \< 100/μL within 7 days of apheresis
  • Known history of infection with (HIV)
  • Known active infection with (hepatitis B surface antigen [HBsAg] positive). If there is a history of treated hepatitis B, the viral load must be polymerase chain reaction (PCR) negative; antiviral prophylaxis is required if HBsAg negative and anti-hepatitis B core (HBc) positive
  • Known active infection with virus (anti-HCV antibody positive). If patient has a positive hepatitis C antibody, the viral load must be undetectable per quantitative PCR and/or nucleic acid testing
  • No seizure history within 6 months prior to enrollment
  • Known history of cerebral vascular accident (CVA) within prior 12 months
  • Known history or presence of CNS disease, such as multiple sclerosis, optic neuritis or other immunologic /or inflammatory diseases
  • Presence of active CNS disorder that, in the judgment of the investigator, may impair the ability to evaluate neurotoxicity
  • Uncontrolled bacterial, viral, or fungal infection at the time of enrollment.

    a. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment

  • Pregnant or breast-feeding woman
  • Previous or concurrent with the following exceptions:

    1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
    2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 2 years prior to the study
    3. Adequately treated breast or prostate carcinoma on hormonal therapies such as Lupron or tamoxifen and in clinical remission of ≥ 2 years -or- low-grade untreated prostate cancer under observation
    4. A primary malignancy which has been completely resected / treated with curative intent and in complete remission of ≥ 2 years
    5. Subjects with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with safety and efficacy assessment are eligible for this trial after discussion with protocol chair or protocol officer
  • Severely participants e.g. due to current systemic treatment of non-neurologic autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus)
  • Medical condition requiring prolonged use of systemic equivalent to prednisone >10 mg/day.
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other cardiac disease within 6 months of enrollment
  • For systemic therapy or radiation therapy, at least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed at the time of scheduled leukapheresis
  • BTKis can be continued through apheresis until one day prior to start of lymphodepletion
  • Baseline neurologic deficits that would interfere with therapy or monitoring, determined using Immune Effector Cell-Associated Encephalopathy (ICE) Assessment at baseline
  • History of severe immediate reaction to any of the agents in this study
  • Refusal or inability to participate in additional lentiviral gene therapy long-term follow-up (LTFU) protocol
  • Prior CAR-T therapy for any indication or systemic gene-modifying therapy for B cell lymphoma
  • Prior stem cell transplant for any indication.
  • Prior bispecific T cell engaging (BITE) antibodies for cancer therapy
  • Prior T cell receptor-engineered T cell therapy
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Single, open label

    Biological: zamtocabtagene autoleucel (MB-CART2019.1) · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    The primary endpoint is PFS at 1-year following MB2019.1 CAR T cell infusion. PFS is defined as the time interval from CAR T cell infusion until a PFS event occurs.

    Time frame: 1 year post-infusion

Secondary outcomes

  1. Treatment Response

    Treatment response will be assessed using Lugano Criteria (Cheson et al, 2014). Both best overall response and Day 90 response following CAR T cell infusion will be evaluated.

    Time frame: 1 year

  2. Overall Survival (OS)

    Events for OS include deaths from any cause. OS is defined as the time interval from CAR T cell infusion until death.

    Time frame: 1 year post-infusion

  3. Duration of Complete Response (DOCR)

    DOCR is defined as the time from a participant's first achieving a CR until either a disease progression occurs per 2014 Lugano or IPCG criteria or death, whichever occurs first. DOCR will be evaluated in the set of participants who achieve a CR.

    Time frame: 1 year post-infusion

  4. Non-relapse Mortality (NRM)

    Events for NRM include deaths without prior relapse/progression of the underlying malignancy. Relapse/progression is treated as a competing risk for NRM.

    Time frame: 1 year post-infusion

  5. Relapse/progression

    Relapse/progression events will be determined per Lugano criteria.

    Time frame: 1 year post-infusion

  6. IEC Related Toxicities

    CRS, ICANS, and IEC-HS will be determined per ASTCT criteria. The incidence and severity of each of these toxicities within 28 days of CAR T cell infusion will be reported. The incidence and severity of Grade 3 or higher ICANS occurring after Day 28 post-CAR T cell infusion will be reported.

    Time frame: Up to 1 year post-infusion

  7. Event-free Survival (EFS)

    Events for EFS include clinical progression, additional anti-lymphoma treatment initiation (oral therapy, radiation) in the absence of clinical progression, and death. EFS is defined as the time interval from CAR T cell infusion until an EFS event occurs.

    Time frame: 1 year-post infusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 36 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 6, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2029
CompletionEst.
Mar 2030
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569965
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
May 6, 2026

Study contacts

Sadie Swift
Contact
clinicaltrials@miltenyi.com
617-218-0044
Erick Flores
Contact
clinicaltrials@miltenyi.com
617-218-0044

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamtocabtagene autoleucel

Start the discussion